GlobeNewswire

Maricopa Region 911 Calls on Corvil to Bolster Emergency Response Services

Dela

Insight from Corvil Analytics helps assure public safety through optimal caller interaction and servicing

NEW YORK, March 28, 2018 (GLOBE NEWSWIRE) -- Maricopa Region 911, servicing the Phoenix metro area, which includes the fifth largest city in the US, has enlisted Corvil to provide real-time visibility and analytics to assure the quality, performance, and availability of critical emergency communications services across its existing Emergency Services IP network (ESInet), part of Maricopa Region 911's Next Generation 9-1-1 (NG911) deployment.

Delivering nearly 2.5 million wireless calls each year for police, fire, and medical assistance to 27 Public Service Answering Point (PSAP) locations across the region, Maricopa Region 911 provides potentially lifesaving technologies including 911 call delivery and advanced mapping to provide location intelligence using internet-based imagery to hundreds of 911 call taking positions.

Maricopa Region 911 has been moving towards VoIP call delivery, with continuity of operations as a prerequisite. This replaces analog emergency call services with digital communications services and allows for additional NG911 applications, provided over a converged network with increased service assurance requirements.  Maricopa Region 911 deployed Corvil to gain the operational intelligence required to support consistent end-to-end quality of service, with Corvil now providing visibility into the more than 70 percent of calls that have already migrated to VoIP.

"Corvil is providing analytics and actionable insight into our network traffic that previously wasn't available," said Dave Dansevicus, 911 Integrated Systems Administrator.  "Right out of the box, Corvil identified a vendor configuration issue, enabling us to proactively improve performance.  Now, these insights allow one person to get data needed to troubleshoot in minutes, where previously it would require multiple entities and could take over a day.  It seems we find a new use case enabled by Corvil every week." 

Corvil's real-time network analytics empower Maricopa Region 911 with the insight required to meet their "zero tolerance" objective for poor caller experience such as jittery, choppy or garbled calls.  Offering live and retrospective quality metrics such as mean opinion scores, jitter, and packet loss by caller number, time of day, call volumes and other call record details, Corvil delivers advanced, data-driven analytics to proactively identify service degradation, optimize performance, and respond to issues.

"We are proud and delighted to be working with Maricopa Region 911 to support such an important public safety service,"  said Dan Kennedy, Corvil VP and General Manager, Americas.  "Working together to deliver a quality service outcome, we have established a strong partnership that we believe will continue to deliver value well into the future."

Corvil is also delivering operational efficiencies. Through seamless integration with the existing IT Operations Analytics (ITOA) ecosystem, Corvil allows Maricopa Region 911 to maintain the single user interface with which all technical team members are already familiar, thereby extending Corvil intelligence to the broader team, minimizing the learning curve for expanded adoption, and shortening troubleshooting times.  Using the Corvil VoIP Performance App for a leading machine data platform, for example, Maricopa Region 911 operational team members use single-click workflows to contextually navigate to further explore more granular details and analysis within Corvil Analytics or export Corvil data to enable offline investigation or sharing with others.

"By supplying near-real-time access to accurate data that can be shared with our partners - using the tools with which we are already familiar - Corvil has already allowed us to eliminate process bottlenecks and shorten troubleshooting times.  This information also validates our data network is performing as we expect - all to ensure the highest level of 911 service to our community,"  said Dansevicus.

" Our partnership with Maricopa Region 911 exemplifies the important role operational analytics play in supporting the quality delivery, assessment, and improvement of critical services ," said David Murray, Corvil Chief Marketing and Business Development Officer.  " It also highlights the value and importance of our seamless integration with existing customer ecosystems to accelerate improved responsiveness, mean time to repair, staff productivity and customer return on investment."            

About Corvil
Corvil is the industry leader for deriving Security, Operational, and Business intelligence from network data. As companies adopt faster and smarter machine technology, it becomes critical to tap into richer and more granular machine data sources to safeguard the transparency, performance and security of critical infrastructure and business applications. The Corvil streaming analytics platform captures, decodes, and learns from network data on the fly, transforming it into machine-time intelligence for network, IT, security and business teams to operate efficiently and securely in this new machine world. Corvil uses an open architecture to integrate the power of its network data analytics with the overall IT ecosystem providing increased automation and greater operational and business value outcomes for its users. The Corvil solution is trusted by leading financial institutions to safeguard their businesses across the globe involving 354 trillion messages with a daily transaction value in excess of $1 trillion.

Learn more about Corvil: Corvil.com | Twitter | LinkedIn

Media Contact
Press Office at Corvil
+353 1 859 1040
pressoffice@corvil.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Corvil via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum